CN111249285B - 口腔用组合物 - Google Patents
口腔用组合物 Download PDFInfo
- Publication number
- CN111249285B CN111249285B CN201911213235.8A CN201911213235A CN111249285B CN 111249285 B CN111249285 B CN 111249285B CN 201911213235 A CN201911213235 A CN 201911213235A CN 111249285 B CN111249285 B CN 111249285B
- Authority
- CN
- China
- Prior art keywords
- cpc
- scc
- oral composition
- present
- gingival
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 88
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims abstract description 75
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims abstract description 75
- 108091005804 Peptidases Proteins 0.000 claims abstract description 34
- 239000004365 Protease Substances 0.000 claims abstract description 34
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 29
- HWDGVJUIHRPKFR-UHFFFAOYSA-I copper;trisodium;18-(2-carboxylatoethyl)-20-(carboxylatomethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18-dihydroporphyrin-21,23-diide-2-carboxylate Chemical compound [Na+].[Na+].[Na+].[Cu+2].N1=C(C(CC([O-])=O)=C2C(C(C)C(C=C3C(=C(C=C)C(=C4)[N-]3)C)=N2)CCC([O-])=O)C(=C([O-])[O-])C(C)=C1C=C1C(CC)=C(C)C4=N1 HWDGVJUIHRPKFR-UHFFFAOYSA-I 0.000 claims abstract description 16
- 229940079841 sodium copper chlorophyllin Drugs 0.000 claims abstract description 16
- 235000013758 sodium copper chlorophyllin Nutrition 0.000 claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 14
- 229930002875 chlorophyll Natural products 0.000 claims description 6
- 235000019804 chlorophyll Nutrition 0.000 claims description 6
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims description 6
- ZIALXKMBHWELGF-UHFFFAOYSA-N [Na].[Cu] Chemical compound [Na].[Cu] ZIALXKMBHWELGF-UHFFFAOYSA-N 0.000 claims description 5
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 36
- 208000028169 periodontal disease Diseases 0.000 abstract description 16
- 230000002265 prevention Effects 0.000 abstract description 2
- -1 fatty acid esters Chemical class 0.000 description 19
- 239000007788 liquid Substances 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 3
- 241000986839 Porphyromonas gingivalis W83 Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- SVIJYLPSHPPVQF-UHFFFAOYSA-N 2-[2,2-diaminoethyl(dodecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCN(CC(N)N)CC(O)=O SVIJYLPSHPPVQF-UHFFFAOYSA-N 0.000 description 2
- AXCXHFKZHDEKTP-NSCUHMNNSA-N 4-methoxycinnamaldehyde Chemical compound COC1=CC=C(\C=C\C=O)C=C1 AXCXHFKZHDEKTP-NSCUHMNNSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 108010035639 carbobenzoxy-histidyl-glutamyl-lysyl-4-methyl-coumaryl-7-amide Proteins 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000010630 cinnamon oil Substances 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- JOZKFWLRHCDGJA-UHFFFAOYSA-N citronellol acetate Chemical compound CC(=O)OCCC(C)CCC=C(C)C JOZKFWLRHCDGJA-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000002070 germicidal effect Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- DTGKSKDOIYIVQL-NQMVMOMDSA-N (+)-Borneol Natural products C1C[C@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-NQMVMOMDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- KRLBLPBPZSSIGH-CSKARUKUSA-N (6e)-3,7-dimethylnona-1,6-dien-3-ol Chemical compound CC\C(C)=C\CCC(C)(O)C=C KRLBLPBPZSSIGH-CSKARUKUSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- JOZKFWLRHCDGJA-LLVKDONJSA-N Citronellyl acetate Natural products CC(=O)OCC[C@H](C)CCC=C(C)C JOZKFWLRHCDGJA-LLVKDONJSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 239000001329 FEMA 3811 Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- WAUOTJNSQGJSSL-UQKRIMTDSA-N [(2s)-2-(methylamino)propanoyl] dodecanoate;sodium Chemical compound [Na].CCCCCCCCCCCC(=O)OC(=O)[C@H](C)NC WAUOTJNSQGJSSL-UQKRIMTDSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- FXNRKXSSLJKNGH-UHFFFAOYSA-L dipotassium;fluoro-dioxido-oxo-$l^{5}-phosphane Chemical compound [K+].[K+].[O-]P([O-])(F)=O FXNRKXSSLJKNGH-UHFFFAOYSA-L 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229940091249 fluoride supplement Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001648 gingival epithelial cell Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940116837 methyleugenol Drugs 0.000 description 1
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229940074371 monofluorophosphate Drugs 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 1
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 description 1
- 235000010434 neohesperidine DC Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007823 ocimene derivatives Chemical class 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- AXCXHFKZHDEKTP-UHFFFAOYSA-N para-methoxycinnamaldehyde Natural products COC1=CC=C(C=CC=O)C=C1 AXCXHFKZHDEKTP-UHFFFAOYSA-N 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003351 prussian blue Drugs 0.000 description 1
- 239000013225 prussian blue Substances 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229960000414 sodium fluoride Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- SLBXZQMMERXQAL-UHFFFAOYSA-M sodium;1-dodecoxy-4-hydroxy-1,4-dioxobutane-2-sulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O SLBXZQMMERXQAL-UHFFFAOYSA-M 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- XJPBRODHZKDRCB-UHFFFAOYSA-N trans-alpha-ocimene Natural products CC(=C)CCC=C(C)C=C XJPBRODHZKDRCB-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及口腔用组合物。[课题]提供:为了牙周病的预防和/或治疗(特别是抑制牙周病进展)而抑制牙龈蛋白酶活性的方案。[解决方案]一种抗牙周病口腔用组合物,其以质量比1:1.2~100或1.2~20:1含有叶绿素铜钠和氯化十六烷基吡啶。
Description
技术领域
本发明涉及口腔用组合物等。
背景技术
Porphyromonas gingivalis(牙龈卟啉单胞菌(P.g菌))是被认为在牙周炎的发病和进展中最重要的牙周病源菌。
作为产生P.g菌的代表性的病原性因子,已知有牙龈蛋白酶。牙龈蛋白酶为蛋白酶的1种,存在有肽切断部位特异性不同的Lys-牙龈蛋白酶(Kgp)和Arg-牙龈蛋白酶(Rgp)。它们边相互作用边引起牙龈上皮细胞间的结合的破坏性、对上皮细胞本身的伤害和/或增殖妨碍、进而上皮屏障的破坏和修复妨碍。另外,牙龈蛋白酶还具有:基于吞噬细胞的吞噬和细胞内抑制消化的效果、以及有助于补体系统的破坏、对上皮细胞内的侵入的效果等,由此,还参与了P.g菌逃避免疫系统。进而,最近,据报道基于牙龈蛋白酶的免疫系统的抑制效果导致口腔内细菌菌群的失调(Dysbiosis),并且这些牙龈蛋白酶的作用导致牙周病的进展和难治性。
现有技术文献
专利文献
专利文献1:国际公开第2016/104524号
发明内容
发明要解决的问题
基于以上的情况,为了牙周病的预防和/或治疗(特别是抑制牙周病进展),重要的是,抑制牙龈蛋白酶活性。
用于解决问题的方案
因此,以发现抑制牙龈蛋白酶活性的手法为目的进行了研究,结果发现:叶绿素铜钠效率良好地抑制牙龈蛋白酶活性。
因此,接着为了制备抑制牙龈蛋白酶活性、且还具备P.g菌的杀菌效果的口腔用组合物,研究了将发挥杀菌效果的成分的氯化十六烷基吡啶与叶绿素铜钠组合而使用。因而,推进了研究,结果发现:如果组合叶绿素铜钠与氯化十六烷基吡啶而使用,则有时无法得到如所期待那样的牙龈蛋白酶活性抑制效果。
因此,将叶绿素铜钠和氯化十六烷基吡啶组合而使用的情况下,以发现能效率良好地抑制牙龈蛋白酶活性的手法为目的,进一步反复研究。
其结果,本发明人等发现如下的可能性:通过以特定的比例组合叶绿素铜钠与氯化十六烷基吡啶而使用,从而可以效率良好地抑制牙龈蛋白酶活性,且与单独使用叶绿素铜钠的情况相比,可以制备杀菌效果还得到改善的口腔用组合物,进一步反复改良,至此完成了本发明。
本发明包含例如以下的项中记载的主题。
项1.
一种口腔用组合物,其以质量比1:1.2~100或1.2~20:1含有叶绿素铜钠和氯化十六烷基吡啶。
项2.
根据项1所述的组合物,其为用于抗牙周病的口腔用组合物。
项3.
根据项2所述的组合物,其中,抗牙周病为抑制牙周病进展。
项4.
根据项1~3中任一项所述的组合物,其含有0.001~0.1质量%的叶绿素铜钠。
项5.
根据项1~4中任一项所述的组合物,其含有0.005~0.1质量%的氯化十六烷基吡啶。
发明的效果
可以提供能效率良好地抑制牙龈蛋白酶活性、且与单独使用叶绿素铜钠的情况相比杀菌效果也得到改善的口腔用组合物。该口腔用组合物对于抗牙周病(特别是抑制牙周病进展)是特别有用的。
附图说明
图1示出研究了基于叶绿素铜钠的牙龈蛋白酶(Kgp和Rgp)的活性的抑制效果的结果。
具体实施方式
以下,对本发明中包含的各实施方式进一步详细进行说明。本发明优选包含口腔用组合物和其用途等,但不应限定于这些,本发明包含本说明书中公开、且本领域技术人员能理解的全部。
本发明中包含的口腔用组合物含有叶绿素铜钠和氯化十六烷基吡啶。以下,将本发明中包含的该口腔用组合物有时称为“本发明的口腔用组合物”。另外,本说明书中,将叶绿素铜钠有时简记作SCC,而且将氯化十六烷基吡啶有时简记作CPC。叶绿素铜钠和氯化十六烷基吡啶均为口腔用组合物领域中使用的公知的成分。这些成分也可以购买市售品而使用。
本发明的口腔用组合物以质量比(SCC:CPC)1:1.2~100或1.2~20:1含有SCC和CPC。
需要说明的是,本次的研究中还发现了基于CPC的杀菌效果有由SCC减弱的可能性。如果与单独使用SCC的情况相比,则将SCC与CPC组合而使用时,杀菌效果提高,但有时难以发挥CPC原本的杀菌效果。从更有效地发挥杀菌效果的观点出发,CPC含量优选与SCC含量为等量或其以上。因此,本发明的口腔用组合物中,从更有效地发挥基于CPC的杀菌效果的观点出发,SCC与CPC的含有质量比(SCC:CPC)更优选1:1.2~100。
本发明的口腔用组合物中的、该SCC和CPC含有质量比(即,1:1.2~100或1.2~20:1)中,有时将SCC的含有比率小的比(即,1:1.2~100)称为质量比(i)。另外,该质量比中,有时将SCC的含有比率大的比(即,1.2~20:1)称为质量比(ii)。
质量比(i)中的CPC含有比率范围(即,1.2~100)的下限例如可以为1.3、1.4、1.5、1.6、1.7、1.8、1.9、2、2.1、2.2、2.3、2.4、2.5、2.6、2.7、2.8、2.9、或3。另外,质量比(i)中的CPC含有比率范围的上限例如可以为95、90、85、80、75、70、65、60、50、45、40、35、30、29、28、27、26、25、24、23、22、21、20、19、18、17、16、15、14、13、12、11、10、9、8、7、6、5、4、3、或2。
质量比(ii)中的SCC含有比率范围(即,1.2~20)的下限例如可以为1.3、1.4、1.5、1.6、1.7、1.8、1.9、2、2.1、2.2、2.3、2.4、2.5、2.6、2.7、2.8、2.9、或3。另外,质量比(ii)中的SCC含有比率范围的上限例如可以为19、18、17、16、15、14、13、12、11、10、9、8、7、6、5、4、3、或2。
本发明的口腔用组合物也可以称为以质量比(SCC:CPC)1:100~20:1含有SCC和CPC的组合物,且其中排除以1:1.2~1.2:1含有的组合物(其中,不排除优选以1:1.2和1.2:1含有的组合物)的口腔用组合物。意外地,随着SCC与CPC的含有质量接近1:1,与由SCC单独发挥的牙龈蛋白酶活性抑制效果相比,组合SCC和CPC而得到的牙龈蛋白酶抑制效果急剧降低。因此,以前述质量比范围(1:1.2~1.2:1)含有SCC和CPC的口腔用组合物从本发明的口腔用组合物中排除(其中,不排除优选以1:1.2和1.2:1含有的组合物)。
需要说明的是,如果为该“排除”的记载方法,则例如本发明的口腔用组合物更优选例如可以称为:以质量比(SCC:CPC)1:100~20:1含有SCC和CPC的组合物,且其中排除以1:1.3~1.3:1含有的组合物(其中,不排除优选以1:1.3和1.3:1含有的组合物)的口腔用组合物;以质量比(SCC:CPC)1:100~20:1含有SCC和CPC的组合物,且其中排除以1:1.4~1.4:1含有的组合物(其中,不排除优选以1:1.4和1.4:1含有的组合物)的口腔用组合物;以质量比(SCC:CPC)1:100~20:1含有SCC和CPC的组合物,且其中排除以1:1.5~1.5:1含有的组合物(其中,不排除优选以1:1.5和1.5:1含有的组合物)的口腔用组合物;以质量比(SCC:CPC)1:100~20:1含有SCC和CPC的组合物,且其中排除以1:1.6~1.6:1含有的组合物(其中,不排除优选以1:1.6和1.6:1含有的组合物)的口腔用组合物;以质量比(SCC:CPC)1:100~20:1含有SCC和CPC的组合物,且其中排除以1:1.7~1.7:1含有的组合物(其中,不排除优选以1:1.7和1.7:1含有的组合物)的口腔用组合物;以质量比(SCC:CPC)1:100~20:1含有SCC和CPC的组合物,且其中排除以1:1.8~1.8:1含有的组合物(其中,不排除优选以1:1.8和1.8:1含有的组合物)的口腔用组合物;以质量比(SCC:CPC)1:100~20:1含有SCC和CPC的组合物,且其中排除以1:1.9~1.9:1含有的组合物(其中,不排除优选以1:1.9和1.9:1含有的组合物)的口腔用组合物;或者,以质量比(SCC:CPC)1:100~20:1含有SCC和CPC的组合物,且其中排除以1:2~2:1含有的组合物(其中,不排除优选以1:2和2:1含有的组合物)的口腔用组合物。另外,关于该SCC与CPC的质量比(1:100~20:1)的“1:100”和“20:1”,分别直接相当于上述“质量比(i)中的CPC含有比率范围的上限”的记载、和“质量比(ii)中的SCC含有比率范围的上限”的记载。
本发明的口腔用组合物中的SCC的含量优选0.001~0.1质量%左右。该范围的下限可以为0.002、0.003、0.004、0.005、0.006、0.007、0.008、0.009、0.01、0.011、0.012、0.013、0.014、或0.015质量%左右。另外,该范围的上限可以为0.09、0.08、0.07、0.06、或0.05质量%左右。
另外,本发明的口腔用组合物中的CPC的含量优选0.005~0.1质量%左右。该范围的下限可以为0.01、0.015、0.02、0.025、0.03、0.035、0.04、0.045、或0.05质量%左右。另外,该范围的上限可以为0.09、0.08、0.07、0.06、或0.05质量%左右。
需要说明的是,CPC的含量如果为0.025质量%以上,则即使CPC含量与SCC含量不是等量或其以上,也可以有效地发挥基于CPC的杀菌效果。因此,从更有效地发挥基于CPC的杀菌效果的观点出发,CPC含量进一步优选0.025质量%以上。
另外,本发明的口腔用组合物特别是为液态口腔用组合物(除液体口腔用组合物之外,还包括凝胶状、膏状等能符合浓度的组合物)的情况下,本发明的口腔用组合物中的SCC的浓度优选10~1000μg/ml。该范围的下限可以为20、30、40、50、60、70、80、90、100、110、120、130、140、或150μg/ml。另外,该范围的上限可以为900、800、700、600、或500μg/ml。
进一步另外,本发明的口腔用组合物特别是为液态口腔用组合物(除液体口腔用组合物之外,还包括凝胶状、膏状等能符合浓度的组合物)的情况下,本发明的口腔用组合物中的CPC的浓度优选50~1000μg/ml。该范围的下限可以为100、150、200、250、300、350、400、450、或500μg/ml。另外,该范围的上限可以为900、800、700、600、或500μg/ml。
需要说明的是,CPC的浓度如果为250μg/ml以上,则即使CPC含量与SCC含量不是等量或其以上也可以有效地发挥基于CPC的杀菌效果。因此,从更有效地发挥基于CPC的杀菌效果的观点出发,CPC浓度进一步优选250μg/ml以上。
需要说明的是,没有特别限制,从特别效率良好地抑制牙龈蛋白酶活性、且也特别效率良好地得到CPC的杀菌效果的观点出发,本发明的口腔用组合物中,特别优选的是,CPC的含量为0.025~0.1质量%左右、SCC含量为0.012~0.1质量%,且其含有质量比(SCC:CPC)为1:2.5~8或1.2~4:1左右。特别是,在本发明的口腔用组合物为液态组合物的情况下,从该观点出发,特别优选的是,CPC的含有浓度为250~1000μg/ml左右、SCC含有浓度为120~1000μg/ml左右,且其含有质量比(SCC:CPC)为1:2.5~8或1.2~4:1左右。
本发明的抗牙周病口腔用组合物可以为固体组合物、液体组合物。该抗牙周病口腔用组合物例如可以作为药品、准药品使用。另外,本发明的抗牙周病口腔用组合物的形态没有特别限定,可以依据常规方法制成例如软膏剂、糊剂、皮肤膏剂、凝胶剂、液剂、喷雾剂、漱口水剂、液体牙膏剂、牙膏剂、口胶剂等形态(剂形)。其中,优选漱口水剂、液体牙膏剂、牙膏剂、软膏剂、糊剂、液剂、凝胶剂。
本发明的抗牙周病口腔用组合物在不有损本发明的效果的范围内可以进一步含有单独或2种以上的能配混于口腔用组合物的任意成分。
例如,作为表面活性剂,可以配混非离子表面活性剂、阴离子表面活性剂或两性表面活性剂。具体而言,例如,作为非离子表面活性剂,可以举出蔗糖脂肪酸酯、麦芽糖脂肪酸酯、乳糖脂肪酸酯等糖脂肪酸酯;脂肪酸烷醇酰胺类;脱水山梨醇脂肪酸酯;脂肪酸单甘油酯;聚氧乙烯加成系数为8~10、烷基的碳数为13~15的聚氧乙烯烷基醚;聚氧乙烯加成系数为10~18、烷基的碳数为9的聚氧乙烯烷基苯基醚;癸二酸二乙酯;聚氧乙烯氢化蓖麻油;脂肪酸聚氧乙烯脱水山梨醇等。作为阴离子表面活性剂,可以举出月桂基硫酸钠、聚氧乙烯月桂基醚硫酸钠等硫酸酯盐;月桂基磺基琥珀酸钠、聚氧乙烯月桂基醚磺基琥珀酸钠等磺基琥珀酸盐;椰油酰肌氨酸钠、月桂酰甲基丙氨酸钠等酰基氨基酸盐;椰油基甲基牛磺酸钠等。作为两性离子表面活性剂,可以举出月桂基二甲基氨基乙酸甜菜碱、椰子油脂肪酸酰胺丙基二甲基氨基乙酸甜菜碱等乙酸甜菜碱型活性剂;N-椰油基-N-羧基甲基-N-羟基乙基乙二胺钠等咪唑啉型活性剂;N-月桂基二氨基乙基甘氨酸等氨基酸型活性剂等。这些表面活性剂可以单独配混或组合2种以上而配混。其配混量通常相对于组合物总量为0.1~5质量%。
另外,作为香味剂,例如可以使用薄荷醇、羧酸、茴香脑、丁香酚、水杨酸甲酯、柠檬烯、罗勒烯、正癸醇、香茅醇、α-松油醇、甲基乙酸酯、乙酸香茅酯、甲基丁香酚、桉树脑、芳樟醇、乙基芳樟醇、百里酚、留兰香油、薄荷油、柠檬油、橙油、鼠尾草油、迷迭香油、肉桂油、紫苏油、鹿蹄草油、丁香油、桉树油、多香果油、d-樟脑、d-冰片、茴香油、肉桂油、肉桂醛、薄荷油、香兰素等香料。它们可以单独配混或组合2种以上以相对于组合物总量例如为0.001~1.5质量%配混。
另外,作为甜味剂,例如可以使用糖精钠、乙酰磺胺酸钾、甜菊糖苷、新橙皮苷二氢查尔酮、紫苏葶、奇异果甜蛋白、天冬氨酰苯丙氨酸甲酯、对甲氧基肉桂醛等。它们可以以相对于组合物总量例如为0.01~1质量%配混。
进而,作为湿润剂,可以单独配混或组合2种以上而配混山梨醇、乙二醇、丙二醇、甘油、1,3-丁二醇、聚丙二醇、木糖醇、麦芽糖醇、乳糖醇、聚氧乙二醇等。
作为防腐剂,可以配混对羟基苯甲酸甲酯、对羟基苯甲酸乙酯、对羟基苯甲酸丙酯、对羟基苯甲酸丁酯等对羟基苯甲酸酯类、苯甲酸钠、苯氧乙醇、烷基二氨基乙基甘氨酸盐酸盐等。
作为着色剂,可以配混蓝色1号、黄色4号、红色202号、绿3号等法定色素、群青、增强群青、普鲁士蓝等矿物系色素、氧化钛等。
作为pH调节剂,可以配混柠檬酸、磷酸、苹果酸、焦磷酸、乳酸、酒石酸、甘油磷酸、乙酸、硝酸、或它们的化学上能形成的盐、氢氧化钠等。它们可以单独配混或组合2种以上而配混使得组合物的pH成为4~8、优选成为5~7的范围。pH调节剂的配混量例如可以为0.01~2重量%。
需要说明的是,本发明的口腔用组合物中,进而,作为药效成分,可以单独配混或组合2种以上而配混dl-α-生育酚乙酸酯、生育酚琥珀酸酯、或生育酚烟酸酯等维生素E类、十二烷基二氨基乙基甘氨酸等两性杀菌剂、三氯生、异丙基甲基苯酚等非离子性杀菌剂、葡聚糖酶、淀粉酶、蛋白酶、非水溶性葡聚糖酶、溶菌酶、溶解酶(Lytic enzyme)等酶、一氟磷酸钠、一氟磷酸钾等碱金属一氟磷酸盐、氟化钠、氟化亚锡等氟化物、氨甲环酸、ε-氨基己酸、铝氯羟尿囊素、二氢胆固醇、甘草次酸、甘草酸、甘油磷酸盐、叶绿素、氯化钠、海狗肽(caropeptide)、尿囊素、肾上腺色素缩氨脲(carbazochrome)、扁柏油酚(hinokitiol)、硝酸钾、异麦芽酮糖醇等。
另外,作为基剂,也可以添加醇类、硅、磷灰石、白色凡士林、石蜡、液体石蜡、微晶蜡、角鲨烷、树指基液等。
另外,本发明的口腔用组合物可以通过公知的方法或由公知的方法容易想到的方法而制备。例如,通过将SCC和CPC以及根据需要的其他成分适宜混合,从而可以制备。
需要说明的是,本说明书中“包含”还包括“本质上由……构成”、和“由……构成”(The term"comprising"includes"consisting essentially of”and"consisting of.")。另外,本发明全部包含任意组合全部本说明书中说明的技术特征。
另外,特定本发明中包含的主题时,对上述本发明的各实施方式说明的各种特性(性质、结构、功能等)可以任意组合。即,本发明中,包含全部由能组合本说明书中记载的各特性的一切组合构成的主题。
实施例
以下,对本发明更具体地进行说明,但本发明不限定于下述的例子。需要说明的是,对于以下药剂(叶绿素铜钠(SCC)、氯化十六烷基吡啶(CPC)、和其混合物)的量,以浓度(μg/mL)表示,所使用的每1ml液体的质量稍大于1g,但也可以认为大致为1ml≒1g。
基于SCC的牙龈蛋白酶活性的抑制效果的研究
将P.g菌(P.gingivalis W83)在GAM培养基中进行培养,调整为吸光度(O.D(600))=1.0。将该菌液以10000rpm进行离心分离,将上清回收。回收后的上清中包含牙龈蛋白酶。将调整为各浓度的叶绿素铜钠(SCC)与回收后的上清混合,放置3分钟。3分钟后,与用PBS稀释了100倍的牙龈蛋白酶的基质(Z-His-Glu-Lys-MCA或Z-Phe-Arg-MCA;株式会社肽研究所)混合,进行避光并在37℃下静置1小时。需要说明的是,Z-His-Glu-Lys-MCA为苄氧羰基-L-组氨酰基-L-谷氨酰基-L-赖氨酸4-甲基香豆基-7-酰胺(Benzyloxycarbonyl-L-Histidyl-L-Glutamyl-L-Lysine 4-methylcoumaryl-7-amide(盐酸盐型)),是由Lys-牙龈蛋白酶(Kgp)活性切断并发出荧光的试剂。另外,Z-Phe-Arg-MCA为苄氧羰基-L-苯丙氨酰基-L-精氨酸4-甲基香豆基-7-酰胺(Benzyloxycarbonyl-L-phenylalanyl-L-arginine 4-methylcoumaryl-7-amide(盐酸盐型)),是由Arg-牙龈蛋白酶(Rgp)活性切断而发出荧光的试剂。1小时后,用荧光酶标仪(Gemini XPS)测定荧光强度(激发光:380nm、释放光:440nm)。进行换算使得药剂浓度为0μg/mL下的荧光强度成为100%,算出各浓度的SCC经处理时的牙龈蛋白酶活性。需要说明的是,在n=2下研究各浓度,算出的值作为平均值。显示算出的值越小、牙龈蛋白酶活性越得到抑制。将结果示于图1。
基于SCC和CPC的P.g菌的牙龈蛋白酶活性的抑制效果的研究
与上述同样地,研究了组合SCC和CPC而使用时的P.g菌的牙龈蛋白酶活性的抑制效果。即,如此进行了研究。将P.g菌(P.gingivalis W83)在GAM培养基中进行培养,调整为吸光度(O.D(600))=1.0。将该菌液以10000rpm进行离心分离,将上清回收。回收后的上清中包含牙龈蛋白酶。将调整为各浓度的药剂(叶绿素铜钠(SCC)、氯化十六烷基吡啶(CPC)、和其混合物)与回收后的上清混合,放置3分钟。3分钟后,与用PBS稀释了100倍的Lys-牙龈蛋白酶(Kgp)的基质(Z-Phe-Arg-MCA;株式会社肽研究所)混合,进行避光并在37℃下静置1小时。1小时后,用荧光酶标仪(Gemini XPS)测定荧光强度(激发光:380nm、释放光:440nm)。进行换算使得药剂浓度为0μg/mL下的荧光强度成为100%,算出各浓度的药剂经处理时的牙龈蛋白酶活性。需要说明的是,在n=2下研究各浓度,算出的值作为平均值。显示算出的值越小、牙龈蛋白酶活性越得到抑制。将结果归纳于表1。
[表1]
基于SCC和CPC的P.g菌杀菌效果的研究
将P.g菌(P.gingivalis W83)在GAM培养基中进行培养,调整为吸光度(O.D(600))=1.0。将调整为各处理浓度的倍的浓度的药剂(叶绿素铜钠(SCC)、氯化十六烷基吡啶(CPC)、和其混合物)与调整后的菌液等量混合,放置3分钟。3分钟后,在该药剂和菌液的混合液中加入1/10量的杀菌剂失活PBS(0.07%卵磷脂+0.5%Tween 80),使杀菌效果停止。之后,在GAM培养基中加入10倍量的该混合液,在37℃厌氧条件下培养16小时。培养后,用吸光酶标仪(xMark微型酶标仪)测定培养基的吸光度(O.D(600)),测定浊度,确认杀菌效果。吸光度越小,菌越不增殖,因此,吸光度越小,杀菌效果可以越高。将结果归纳于表2。
[表2]
Claims (2)
1.叶绿素铜钠和氯化十六烷基吡啶在用于制造抑制牙龈蛋白酶口腔用组合物中的应用,其中,
叶绿素铜钠和氯化十六烷基吡啶的质量比为1:1.2~100或1.2~20:1,
抑制牙龈蛋白酶口腔用组合物为含有0.005~0.09质量%的氯化十六烷基吡啶的抑制牙龈蛋白酶口腔用组合物。
2.根据权利要求1所述的应用,其中,抑制牙龈蛋白酶口腔用组合物为含有0.001~0.1质量%的叶绿素铜钠的抑制牙龈蛋白酶口腔用组合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018226446A JP7143198B2 (ja) | 2018-12-03 | 2018-12-03 | 口腔用組成物 |
JP2018-226446 | 2018-12-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111249285A CN111249285A (zh) | 2020-06-09 |
CN111249285B true CN111249285B (zh) | 2024-03-05 |
Family
ID=70946723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911213235.8A Active CN111249285B (zh) | 2018-12-03 | 2019-12-02 | 口腔用组合物 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP7143198B2 (zh) |
CN (1) | CN111249285B (zh) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1605909A1 (en) * | 2003-02-18 | 2005-12-21 | Quest International Services B.V. | Flavoured mouth wash composition |
JP2006306768A (ja) * | 2005-04-27 | 2006-11-09 | Sunstar Inc | 口腔又は咽喉用殺菌組成物 |
JP2010018546A (ja) * | 2008-07-10 | 2010-01-28 | Nippon Zettoc Co Ltd | コラゲナーゼ阻害剤、皮膚外用剤、口腔用組成物及び食品 |
CN101909589A (zh) * | 2008-01-17 | 2010-12-08 | 日本可乐丽医疗器材株式会社 | 牙科口腔用组合物 |
JP2011132139A (ja) * | 2009-12-22 | 2011-07-07 | Lion Corp | 歯磨組成物 |
JP2012116771A (ja) * | 2010-11-30 | 2012-06-21 | Lion Corp | 口腔用組成物及び歯周病原因菌の歯面付着抑制剤 |
JP2012131726A (ja) * | 2010-12-21 | 2012-07-12 | Lion Corp | 口腔用組成物及びアルジンジパイン活性阻害剤 |
CN103458864A (zh) * | 2011-03-25 | 2013-12-18 | 狮王株式会社 | 液体口腔用组合物以及稳定化混合该组合物中组分的方法 |
JP2016179967A (ja) * | 2015-03-25 | 2016-10-13 | サンスター株式会社 | 水系口腔用組成物 |
JP2016185915A (ja) * | 2015-03-27 | 2016-10-27 | サンスター株式会社 | 水系口腔用組成物 |
CN107205899A (zh) * | 2015-02-06 | 2017-09-26 | 狮王株式会社 | 液体口腔用组合物 |
-
2018
- 2018-12-03 JP JP2018226446A patent/JP7143198B2/ja active Active
-
2019
- 2019-12-02 CN CN201911213235.8A patent/CN111249285B/zh active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1605909A1 (en) * | 2003-02-18 | 2005-12-21 | Quest International Services B.V. | Flavoured mouth wash composition |
JP2006306768A (ja) * | 2005-04-27 | 2006-11-09 | Sunstar Inc | 口腔又は咽喉用殺菌組成物 |
CN101909589A (zh) * | 2008-01-17 | 2010-12-08 | 日本可乐丽医疗器材株式会社 | 牙科口腔用组合物 |
JP2010018546A (ja) * | 2008-07-10 | 2010-01-28 | Nippon Zettoc Co Ltd | コラゲナーゼ阻害剤、皮膚外用剤、口腔用組成物及び食品 |
JP2011132139A (ja) * | 2009-12-22 | 2011-07-07 | Lion Corp | 歯磨組成物 |
JP2012116771A (ja) * | 2010-11-30 | 2012-06-21 | Lion Corp | 口腔用組成物及び歯周病原因菌の歯面付着抑制剤 |
JP2012131726A (ja) * | 2010-12-21 | 2012-07-12 | Lion Corp | 口腔用組成物及びアルジンジパイン活性阻害剤 |
CN103458864A (zh) * | 2011-03-25 | 2013-12-18 | 狮王株式会社 | 液体口腔用组合物以及稳定化混合该组合物中组分的方法 |
CN107205899A (zh) * | 2015-02-06 | 2017-09-26 | 狮王株式会社 | 液体口腔用组合物 |
JP2016179967A (ja) * | 2015-03-25 | 2016-10-13 | サンスター株式会社 | 水系口腔用組成物 |
JP2016185915A (ja) * | 2015-03-27 | 2016-10-27 | サンスター株式会社 | 水系口腔用組成物 |
Non-Patent Citations (2)
Title |
---|
"0.1%西吡氯铵漱口液的体外抗菌试验";李孝权等;《中国微生态学杂志》;第14卷(第6期);第361-362页 * |
"In vitro antimicrobial effects of two antihalitosis mouth rinses on oral pathogens and human tongue microbiota";Raangs, GC等;《INTERNATIONAL JOURNAL OF DENTAL HYGIENE》;20130731;第203-207页 * |
Also Published As
Publication number | Publication date |
---|---|
JP7143198B2 (ja) | 2022-09-28 |
CN111249285A (zh) | 2020-06-09 |
JP2020090440A (ja) | 2020-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020299514B2 (en) | Oral care compositions and methods | |
AU2010363657B2 (en) | Oral care product and methods of use and manufacture thereof | |
EP3544570B1 (en) | Oral care product and methods of use and manufacture thereof | |
EP3368005B1 (en) | Oral care products and methods | |
JP2006312589A (ja) | 口腔用組成物 | |
CN111249285B (zh) | 口腔用组合物 | |
JP7267872B2 (ja) | 口腔用組成物 | |
EP3082728B1 (en) | Method for solubilizing rutin with polyhydroxyalkyl alcohols | |
JP2023004338A (ja) | 口腔用組成物 | |
JP2023004337A (ja) | 口腔用組成物 | |
CN116249527A (zh) | 用于抑制齿菌斑形成的组合物 | |
BR112013011852B1 (pt) | Two-phase mouthwash and its use in the preparation of a medicament for treating diseases and disorders in oral health |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |